Effect of the p53 P72R Polymorphism on Mutant TP53 Allele Selection in Human Cancer
Open Access
- 8 February 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 113 (9) , 1246-1257
Abstract
TP53 mutations occur in more than 50% of cancers. We sought to determine the effect of the intragenic P72R single nucleotide polymorphism (SNP; rs1042522) on the oncogenic properties of mutant p53. P72R allelic selection in tumors was determined from genotype calls and a Gaussian distributed mixture model. The SNP effect on mutant p53 was determined in p53-negative cancer cell lines. RNA-sequencing, chromatin immunoprecipitation, and survival analysis were performed to describe the SNP effect. All statistical tests were 2-sided. Among 409 patients with germline heterozygous P72R SNP who harbored somatic mutations in TP53, we observed a selection bias against missense TP53 mutants encoding the P72 SNP (P = 1.64 x 10-13). Exogenously expressed hotspot p53 mutants with the P72 SNP were negatively selected in cancer cells. Gene expression analyses showed the enrichment of p53 pathway genes and inflammatory genes in cancer cells transduced with mutants encoding P72 SNP. Immune gene signature is enriched in patients harboring missense TP53 mutations with homozygous P72 SNP. These patients have improved overall survival as compared with those with the R72 SNP (P = .04). This is the largest study demonstrating a selection against the P72 SNP. Missense p53 mutants with the P72 SNP retain partial wild-type tumor-suppressive functions, which may explain the selection bias against P72 SNP across cancer types. Ovarian cancer patients with the P72 SNP have a better prognosis than with the R72 SNP. Our study describes a previously unknown role through which the rs1042522 SNP modifies tumor suppressor activities of mutant p53 in patients.Keywords
Funding Information
- Department of Defense (W81XWH-10-10386)
- Kansas Institute for Precision Medicine Centers of Biomedical Research Excellence
- National Institute of General Medical Science award (P20 GM130423)
- Flow Cytometry Core Laboratory at the University of Kansas Medical Center
- NIH/NIGMS CoBRE (P30 GM103326)
- NIH/NCI Cancer Center (P30 CA168524)
- UNM Comprehensive Cancer Center Support (P30 CA11810)
- UC Davis Comprehensive Cancer Center Support (P30 CA093373)
- NIH
This publication has 44 references indexed in Scilit:
- CSF1 Is a Novel p53 Target Gene Whose Protein Product Functions in a Feed-Forward Manner to Suppress Apoptosis and Enhance p53-Mediated Growth ArrestPLOS ONE, 2013
- Ab initio protein structure assembly using continuous structure fragments and optimized knowledge‐based force fieldProteins: Structure, Function, and Bioinformatics, 2012
- The first 30 years of p53: growing ever more complexNature Reviews Cancer, 2009
- Winter Temperature and UV Are Tightly Linked to Genetic Changes in the p53 Tumor Suppressor Pathway in Eastern AsiaThe American Journal of Human Genetics, 2009
- Genome-Wide Mapping of in Vivo Protein-DNA InteractionsScience, 2007
- GenePattern 2.0Nature Genetics, 2006
- p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patientsPharmacogenetics and Genomics, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- The codon 72 polymorphic variants of p53 have markedly different apoptotic potentialNature Genetics, 2003
- p53 Mutations in Human CancersScience, 1991